Multiple Myeloma Hub cover image

What are the pros and cons of bispecific antibodies for multiple myeloma?

Multiple Myeloma Hub

CHAPTER

Comparing CARTY Cells and Bi-specific Antibodies in Multiple Myeloma Treatment

Speakers discuss the effectiveness and considerations of CARTY cells versus bi-specific antibodies for multiple myeloma patients, highlighting the evolving landscape of therapies and emphasizing the importance of individualized patient choices.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner